Barclays Maintains Overweight on HCA Healthcare, Raises Price Target to $367
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on HCA Healthcare and raises the price target from $356 to $367.
April 29, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on HCA Healthcare and increases the price target to $367.
The upgrade in the price target by Barclays reflects a positive outlook on HCA Healthcare's stock, likely due to strong financial performance or growth prospects. This analyst endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100